BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Akanmu MA, Honda K. Selective stimulation of orexin receptor type 2 promotes wakefulness in freely behaving rats. Brain Research 2005;1048:138-45. [DOI: 10.1016/j.brainres.2005.04.064] [Cited by in Crossref: 52] [Cited by in F6Publishing: 53] [Article Influence: 3.1] [Reference Citation Analysis]
Number Citing Articles
1 Kambe D, Kotani M, Yoshimoto M, Kaku S, Chaki S, Honda K. Effects of quercetin on the sleep–wake cycle in rats: Involvement of gamma-aminobutyric acid receptor type A in regulation of rapid eye movement sleep. Brain Research 2010;1330:83-8. [DOI: 10.1016/j.brainres.2010.03.033] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
2 Qi K, Wei C, Li Y, Sui N. Orexin receptors within the nucleus accumbens shell mediate the stress but not drug priming-induced reinstatement of morphine conditioned place preference. Front Behav Neurosci 2013;7:144. [PMID: 24133421 DOI: 10.3389/fnbeh.2013.00144] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
3 Roecker AJ, Mercer SP, Schreier JD, Cox CD, Fraley ME, Steen JT, Lemaire W, Bruno JG, Harrell CM, Garson SL, Gotter AL, Fox SV, Stevens J, Tannenbaum PL, Prueksaritanont T, Cabalu TD, Cui D, Stellabott J, Hartman GD, Young SD, Winrow CJ, Renger JJ, Coleman PJ. Discovery of 5''-chloro-N-[(5,6-dimethoxypyridin-2-yl)methyl]-2,2':5',3''-terpyridine-3'-carboxamide (MK-1064): a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia. ChemMedChem 2014;9:311-22. [PMID: 24376006 DOI: 10.1002/cmdc.201300447] [Cited by in Crossref: 48] [Cited by in F6Publishing: 39] [Article Influence: 5.3] [Reference Citation Analysis]
4 Cole S, Mayer HS, Petrovich GD. Orexin/Hypocretin-1 Receptor Antagonism Selectively Reduces Cue-Induced Feeding in Sated Rats and Recruits Medial Prefrontal Cortex and Thalamus. Sci Rep 2015;5:16143. [PMID: 26536818 DOI: 10.1038/srep16143] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 4.7] [Reference Citation Analysis]
5 Magdaleno-madrigal VM, Morales-mulia S, Nicolini H, Genis-mendoza A, Cázares-martínez Claudia E, Pérez-luna José M, Morales-mulia M. Orexin-A promotes EEG changes but fails to induce anxiety in rats. Behavioural Brain Research 2019;361:26-31. [DOI: 10.1016/j.bbr.2018.12.037] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
6 Pekala D, Blasiak T, Raastad M, Lewandowski MH. The influence of orexins on the firing rate and pattern of rat intergeniculate leaflet neurons - electrophysiological and immunohistological studies: Influence of orexins on intergeniculate leaflet. European Journal of Neuroscience 2011;34:1406-18. [DOI: 10.1111/j.1460-9568.2011.07868.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.7] [Reference Citation Analysis]
7 Hikichi H, Hiyoshi T, Marumo T, Tomishima Y, Kaku A, Iida I, Urabe H, Tamita T, Yasuhara A, Karasawa J, Chaki S. Antipsychotic profiles of TASP0443294, a novel and orally active positive allosteric modulator of metabotropic glutamate 2 receptor. J Pharmacol Sci 2015;127:352-61. [PMID: 25837934 DOI: 10.1016/j.jphs.2015.02.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
8 Mahler SV, Smith RJ, Moorman DE, Sartor GC, Aston-Jones G. Multiple roles for orexin/hypocretin in addiction. Prog Brain Res 2012;198:79-121. [PMID: 22813971 DOI: 10.1016/B978-0-444-59489-1.00007-0] [Cited by in Crossref: 140] [Cited by in F6Publishing: 76] [Article Influence: 14.0] [Reference Citation Analysis]
9 Cason AM, Smith RJ, Tahsili-Fahadan P, Moorman DE, Sartor GC, Aston-Jones G. Role of orexin/hypocretin in reward-seeking and addiction: implications for obesity. Physiol Behav 2010;100:419-28. [PMID: 20338186 DOI: 10.1016/j.physbeh.2010.03.009] [Cited by in Crossref: 155] [Cited by in F6Publishing: 150] [Article Influence: 12.9] [Reference Citation Analysis]
10 Prud'homme MJ, Lacroix MC, Badonnel K, Gougis S, Baly C, Salesse R, Caillol M. Nutritional status modulates behavioural and olfactory bulb Fos responses to isoamyl acetate or food odour in rats: roles of orexins and leptin. Neuroscience 2009;162:1287-98. [PMID: 19477242 DOI: 10.1016/j.neuroscience.2009.05.043] [Cited by in Crossref: 56] [Cited by in F6Publishing: 57] [Article Influence: 4.3] [Reference Citation Analysis]
11 Farahimanesh S, Zarrabian S, Haghparast A. Role of orexin receptors in the ventral tegmental area on acquisition and expression of morphine-induced conditioned place preference in the rats. Neuropeptides 2017;66:45-51. [PMID: 28890208 DOI: 10.1016/j.npep.2017.08.003] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
12 Borgland SL, Storm E, Bonci A. Orexin B/hypocretin 2 increases glutamatergic transmission to ventral tegmental area neurons. Eur J Neurosci 2008;28:1545-56. [PMID: 18793323 DOI: 10.1111/j.1460-9568.2008.06397.x] [Cited by in Crossref: 96] [Cited by in F6Publishing: 93] [Article Influence: 6.9] [Reference Citation Analysis]
13 Teske J, Billington C, Kotz C. Neuropeptidergic Mediators of Spontaneous Physical Activity and Non-Exercise Activity Thermogenesis. Neuroendocrinology 2008;87:71-90. [DOI: 10.1159/000110802] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 3.8] [Reference Citation Analysis]
14 Hoever P, Hay J, Rad M, Cavallaro M, van Gerven JM, Dingemanse J. Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Dose Almorexant, an Orexin Receptor Antagonist, in Healthy Elderly Subjects. Journal of Clinical Psychopharmacology 2013;33:363-70. [DOI: 10.1097/jcp.0b013e31828f5a7a] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
15 Cox CD, Breslin MJ, Whitman DB, Schreier JD, McGaughey GB, Bogusky MJ, Roecker AJ, Mercer SP, Bednar RA, Lemaire W, Bruno JG, Reiss DR, Harrell CM, Murphy KL, Garson SL, Doran SM, Prueksaritanont T, Anderson WB, Tang C, Roller S, Cabalu TD, Cui D, Hartman GD, Young SD, Koblan KS, Winrow CJ, Renger JJ, Coleman PJ. Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia. J Med Chem 2010;53:5320-32. [PMID: 20565075 DOI: 10.1021/jm100541c] [Cited by in Crossref: 242] [Cited by in F6Publishing: 217] [Article Influence: 20.2] [Reference Citation Analysis]
16 Asadi S, Roohbakhsh A, Shamsizadeh A, Fereidoni M, Kordijaz E, Moghimi A. The effect of intracerebroventricular administration of orexin receptor type 2 antagonist on pentylenetetrazol-induced kindled seizures and anxiety in rats. BMC Neurosci 2018;19:49. [PMID: 30103703 DOI: 10.1186/s12868-018-0445-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
17 Cason AM, Aston-Jones G. Role of orexin/hypocretin in conditioned sucrose-seeking in rats. Psychopharmacology (Berl) 2013;226:155-65. [PMID: 23096770 DOI: 10.1007/s00213-012-2902-y] [Cited by in Crossref: 73] [Cited by in F6Publishing: 64] [Article Influence: 7.3] [Reference Citation Analysis]
18 Morairty SR, Wisor J, Silveira K, Sinko W, Kilduff TS. The wake-promoting effects of hypocretin-1 are attenuated in old rats. Neurobiol Aging 2011;32:1514-27. [PMID: 19781813 DOI: 10.1016/j.neurobiolaging.2009.07.017] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
19 Mieda M, Hasegawa E, Kisanuki YY, Sinton CM, Yanagisawa M, Sakurai T. Differential roles of orexin receptor-1 and -2 in the regulation of non-REM and REM sleep. J Neurosci 2011;31:6518-26. [PMID: 21525292 DOI: 10.1523/JNEUROSCI.6506-10.2011] [Cited by in Crossref: 134] [Cited by in F6Publishing: 78] [Article Influence: 12.2] [Reference Citation Analysis]
20 Morairty SR, Revel FG, Malherbe P, Moreau JL, Valladao D, Wettstein JG, Kilduff TS, Borroni E. Dual hypocretin receptor antagonism is more effective for sleep promotion than antagonism of either receptor alone. PLoS One 2012;7:e39131. [PMID: 22768296 DOI: 10.1371/journal.pone.0039131] [Cited by in Crossref: 79] [Cited by in F6Publishing: 89] [Article Influence: 7.9] [Reference Citation Analysis]
21 Silverman RB, Holladay MW. Receptors. The Organic Chemistry of Drug Design and Drug Action. Elsevier; 2014. pp. 123-63. [DOI: 10.1016/b978-0-12-382030-3.00003-9] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
22 Weinhold SL, Seeck-Hirschner M, Nowak A, Hallschmid M, Göder R, Baier PC. The effect of intranasal orexin-A (hypocretin-1) on sleep, wakefulness and attention in narcolepsy with cataplexy. Behav Brain Res 2014;262:8-13. [PMID: 24406723 DOI: 10.1016/j.bbr.2013.12.045] [Cited by in Crossref: 60] [Cited by in F6Publishing: 61] [Article Influence: 7.5] [Reference Citation Analysis]
23 Dugovic C, Shelton JE, Aluisio LE, Fraser IC, Jiang X, Sutton SW, Bonaventure P, Yun S, Li X, Lord B, Dvorak CA, Carruthers NI, Lovenberg TW. Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat. J Pharmacol Exp Ther 2009;330:142-51. [PMID: 19363060 DOI: 10.1124/jpet.109.152009] [Cited by in Crossref: 150] [Cited by in F6Publishing: 154] [Article Influence: 11.5] [Reference Citation Analysis]
24 Ghanemi A, Hu X. Targeting the orexinergic system: Mainly but not only for sleep-wakefulness therapies. Alexandria Journal of Medicine 2015;51:279-86. [DOI: 10.1016/j.ajme.2014.07.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
25 Aston-Jones G, Smith RJ, Sartor GC, Moorman DE, Massi L, Tahsili-Fahadan P, Richardson KA. Lateral hypothalamic orexin/hypocretin neurons: A role in reward-seeking and addiction. Brain Res 2010;1314:74-90. [PMID: 19815001 DOI: 10.1016/j.brainres.2009.09.106] [Cited by in Crossref: 238] [Cited by in F6Publishing: 242] [Article Influence: 18.3] [Reference Citation Analysis]
26 Adeghate E. Orexins: tissue localization, functions, and its relation to insulin secretion and diabetes mellitus. Vitam Horm. 2012;89:111-133. [PMID: 22640611 DOI: 10.1016/b978-0-12-394623-2.00007-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
27 Beig MI, Dampney BW, Carrive P. Both Ox1r and Ox2r orexin receptors contribute to the cardiovascular and locomotor components of the novelty stress response in the rat. Neuropharmacology 2015;89:146-56. [PMID: 25239810 DOI: 10.1016/j.neuropharm.2014.09.012] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
28 Roecker AJ, Reger TS, Mattern MC, Mercer SP, Bergman JM, Schreier JD, Cube RV, Cox CD, Li D, Lemaire W, Bruno JG, Harrell CM, Garson SL, Gotter AL, Fox SV, Stevens J, Tannenbaum PL, Prueksaritanont T, Cabalu TD, Cui D, Stellabott J, Hartman GD, Young SD, Winrow CJ, Renger JJ, Coleman PJ. Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia. Bioorg Med Chem Lett 2014;24:4884-90. [PMID: 25248679 DOI: 10.1016/j.bmcl.2014.08.041] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
29 Smith RJ, See RE, Aston-Jones G. Orexin/hypocretin signaling at the orexin 1 receptor regulates cue-elicited cocaine-seeking. Eur J Neurosci 2009;30:493-503. [PMID: 19656173 DOI: 10.1111/j.1460-9568.2009.06844.x] [Cited by in Crossref: 157] [Cited by in F6Publishing: 151] [Article Influence: 12.1] [Reference Citation Analysis]
30 Malherbe P, Borroni E, Pinard E, Wettstein JG, Knoflach F. Biochemical and Electrophysiological Characterization of Almorexant, a Dual Orexin 1 Receptor (OX 1 )/Orexin 2 Receptor (OX 2 ) Antagonist: Comparison with Selective OX 1 and OX 2 Antagonists. Mol Pharmacol 2009;76:618-31. [DOI: 10.1124/mol.109.055152] [Cited by in Crossref: 54] [Cited by in F6Publishing: 58] [Article Influence: 4.2] [Reference Citation Analysis]
31 Adamantidis A, Carter MC, de Lecea L. Optogenetic deconstruction of sleep-wake circuitry in the brain. Front Mol Neurosci 2010;2:31. [PMID: 20126433 DOI: 10.3389/neuro.02.031.2009] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 2.6] [Reference Citation Analysis]
32 Pérez-morales M, De La Herrán-arita AK, Méndez-díaz M, Ruiz-contreras AE, Drucker-colín R, Prospéro-garcía O. 2-AG into the lateral hypothalamus increases REM sleep and cFos expression in melanin concentrating hormone neurons in rats. Pharmacology Biochemistry and Behavior 2013;108:1-7. [DOI: 10.1016/j.pbb.2013.04.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
33 Lalovic B, Majid O, Aluri J, Landry I, Moline M, Hussein Z. Population Pharmacokinetics and Exposure-Response Analyses for the Most Frequent Adverse Events Following Treatment With Lemborexant, an Orexin Receptor Antagonist, in Subjects With Insomnia Disorder. J Clin Pharmacol 2020;60:1642-54. [PMID: 32666570 DOI: 10.1002/jcph.1683] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
34 Inoue Y, Watanabe T, Takashima S, Takase T, Ishikawa K, Kubota N, Yardley J, Moline M. Efficacy and safety of lemborexant in adults with insomnia: comparing Japanese and non-Japanese subgroups from the global, phase 3, randomized, double-blind, placebo-controlled SUNRISE 2 study. J Clin Sleep Med 2021;17:1067-74. [PMID: 33576735 DOI: 10.5664/jcsm.9148] [Reference Citation Analysis]
35 Gotter AL, Webber AL, Coleman PJ, Renger JJ, Winrow CJ. International Union of Basic and Clinical Pharmacology. LXXXVI. Orexin Receptor Function, Nomenclature and Pharmacology. Pharmacol Rev 2012;64:389-420. [DOI: 10.1124/pr.111.005546] [Cited by in Crossref: 114] [Cited by in F6Publishing: 107] [Article Influence: 11.4] [Reference Citation Analysis]
36 Baimel C, Borgland SL. Hypocretin modulation of drug-induced synaptic plasticity. Prog Brain Res 2012;198:123-31. [PMID: 22813972 DOI: 10.1016/B978-0-444-59489-1.00008-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
37 Akanmu MA, Ukponmwan OE, Katayama Y, Honda K. Neuropeptide-Y Y2-receptor agonist, PYY3–36 promotes non-rapid eye movement sleep in rat. Neuroscience Research 2006;54:165-70. [DOI: 10.1016/j.neures.2005.11.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
38 Bjorness TE, Greene RW. Interaction between cocaine use and sleep behavior: A comprehensive review of cocaine's disrupting influence on sleep behavior and sleep disruptions influence on reward seeking. Pharmacol Biochem Behav 2021;206:173194. [PMID: 33940055 DOI: 10.1016/j.pbb.2021.173194] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
39 Yoshida Y, Naoe Y, Terauchi T, Ozaki F, Doko T, Takemura A, Tanaka T, Sorimachi K, Beuckmann CT, Suzuki M, Ueno T, Ozaki S, Yonaga M. Discovery of (1R,2S)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecarboxamide (E2006): A Potent and Efficacious Oral Orexin Receptor Antagonist. J Med Chem 2015;58:4648-64. [PMID: 25953512 DOI: 10.1021/acs.jmedchem.5b00217] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 6.1] [Reference Citation Analysis]
40 Deng BS, Nakamura A, Zhang W, Yanagisawa M, Fukuda Y, Kuwaki T. Contribution of orexin in hypercapnic chemoreflex: evidence from genetic and pharmacological disruption and supplementation studies in mice. J Appl Physiol (1985) 2007;103:1772-9. [PMID: 17717124 DOI: 10.1152/japplphysiol.00075.2007] [Cited by in Crossref: 81] [Cited by in F6Publishing: 83] [Article Influence: 5.4] [Reference Citation Analysis]
41 Weinhold SL, Göder R, Baier PC. Pathway and Effect of Intranasal Orexin. In: Sakurai T, Pandi-perumal S, Monti JM, editors. Orexin and Sleep. Cham: Springer International Publishing; 2015. pp. 339-51. [DOI: 10.1007/978-3-319-23078-8_18] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
42 Coleman P, de Lecea L, Gotter A, Hagan J, Hoyer D, Kilduff T, Kukkonen JP, Porter R, Renger J, Siegel JM, Sutcliffe G, Upton N, Winrow CJ. Orexin receptors in GtoPdb v.2021.3. IUPHAR BPS Guide Pharm CITE 2021;2021. [PMID: 34927075 DOI: 10.2218/gtopdb/f51/2021.3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Kishi T, Nishida M, Koebis M, Taninaga T, Muramoto K, Kubota N, Moline M, Sakuma K, Okuya M, Nomura I, Iwata N. Evidence-based insomnia treatment strategy using novel orexin antagonists: A review. Neuropsychopharmacol Rep 2021. [PMID: 34553844 DOI: 10.1002/npr2.12205] [Reference Citation Analysis]
44 Yoshida Y, Terauchi T, Naoe Y, Kazuta Y, Ozaki F, Beuckmann CT, Nakagawa M, Suzuki M, Kushida I, Takenaka O, Ueno T, Yonaga M. Design, synthesis, and structure-activity relationships of a series of novel N-aryl-2-phenylcyclopropanecarboxamide that are potent and orally active orexin receptor antagonists. Bioorg Med Chem 2014;22:6071-88. [PMID: 25267004 DOI: 10.1016/j.bmc.2014.08.034] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
45 Thompson JL, Borgland SL. A role for hypocretin/orexin in motivation. Behav Brain Res 2011;217:446-53. [PMID: 20920531 DOI: 10.1016/j.bbr.2010.09.028] [Cited by in Crossref: 68] [Cited by in F6Publishing: 74] [Article Influence: 6.2] [Reference Citation Analysis]
46 Haghparast A, Fatahi Z, Arezoomandan R, Karimi S, Taslimi Z, Zarrabian S. Functional roles of orexin/hypocretin receptors in reward circuit. Prog Brain Res 2017;235:139-54. [PMID: 29054286 DOI: 10.1016/bs.pbr.2017.08.005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
47 Borgland SL, Ungless MA, Bonci A. Convergent actions of orexin/hypocretin and CRF on dopamine neurons: Emerging players in addiction. Brain Res 2010;1314:139-44. [PMID: 19891960 DOI: 10.1016/j.brainres.2009.10.068] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 3.8] [Reference Citation Analysis]
48 Ozawa M, Honda K, Nakai I, Kishida A, Ohsaki A. Hypaphorine, an indole alkaloid from Erythrina velutina, induced sleep on normal mice. Bioorganic & Medicinal Chemistry Letters 2008;18:3992-4. [DOI: 10.1016/j.bmcl.2008.06.002] [Cited by in Crossref: 37] [Cited by in F6Publishing: 27] [Article Influence: 2.6] [Reference Citation Analysis]
49 Whitman DB, Cox CD, Breslin MJ, Brashear KM, Schreier JD, Bogusky MJ, Bednar RA, Lemaire W, Bruno JG, Hartman GD, Reiss DR, Harrell CM, Kraus RL, Li Y, Garson SL, Doran SM, Prueksaritanont T, Li C, Winrow CJ, Koblan KS, Renger JJ, Coleman PJ. Discovery of a potent, CNS-penetrant orexin receptor antagonist based on an n,n-disubstituted-1,4-diazepane scaffold that promotes sleep in rats. ChemMedChem 2009;4:1069-74. [PMID: 19418500 DOI: 10.1002/cmdc.200900069] [Cited by in Crossref: 56] [Cited by in F6Publishing: 47] [Article Influence: 4.3] [Reference Citation Analysis]
50 Flores A, Maldonado R, Berrendero F. Cannabinoid-hypocretin cross-talk in the central nervous system: what we know so far. Front Neurosci 2013;7:256. [PMID: 24391536 DOI: 10.3389/fnins.2013.00256] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
51 Kummangal BA, Kumar D, Mallick HN. Intracerebroventricular injection of orexin-2 receptor antagonist promotes REM sleep. Behavioural Brain Research 2013;237:59-62. [DOI: 10.1016/j.bbr.2012.09.015] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
52 Winrow CJ, Gotter AL, Cox CD, Doran SM, Tannenbaum PL, Breslin MJ, Garson SL, Fox SV, Harrell CM, Stevens J, Reiss DR, Cui D, Coleman PJ, Renger JJ. Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist. J Neurogenet 2011;25:52-61. [PMID: 21473737 DOI: 10.3109/01677063.2011.566953] [Cited by in Crossref: 179] [Cited by in F6Publishing: 166] [Article Influence: 16.3] [Reference Citation Analysis]
53 Suzuki J, Ogawa M, Tamura N, Maejima Y, Takayama K, Maemura K, Honda K, Hirata Y, Nagai R, Isobe M. A critical role of sympathetic nerve regulation for the treatment of impaired daily rhythm in hypertensive Dahl rats. Hypertens Res 2010;33:1060-5. [PMID: 20668456 DOI: 10.1038/hr.2010.125] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
54 Mang GM, Dürst T, Bürki H, Imobersteg S, Abramowski D, Schuepbach E, Hoyer D, Fendt M, Gee CE. The dual orexin receptor antagonist almorexant induces sleep and decreases orexin-induced locomotion by blocking orexin 2 receptors. Sleep 2012;35:1625-35. [PMID: 23204605 DOI: 10.5665/sleep.2232] [Cited by in Crossref: 61] [Cited by in F6Publishing: 61] [Article Influence: 6.1] [Reference Citation Analysis]
55 Zlebnik NE, Holtz NA, Lepak VC, Saykao AT, Zhang Y, Carroll ME. Age-specific treatment effects of orexin/hypocretin-receptor antagonism on methamphetamine-seeking behavior. Drug Alcohol Depend 2021;224:108719. [PMID: 33940327 DOI: 10.1016/j.drugalcdep.2021.108719] [Reference Citation Analysis]